65,437 trials
HIV-1
Primary: Change From Baseline in Log 10 Transformed Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) at Month 3 — -1.10 copies/mL
Aids, Cdc Group I
Primary: Tolerability and Safety of the Treatment. — 0; 0 participants
Carotid Atherosclerosis · Carotid Intimal Medial Thickness 1
Primary: Table 1 Study Specific Characteristic Part One — 69.8; 59.8; 59.1; 72.7 Percentage of Participants — p=>0.05
Emergencies
Primary: Triage Time — 126.7; 94.4 Seconds — p=<0.0005
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 2.89; 2.76; 2.37; 1.54 months — p=0.756
Cognition
Primary: Change From Baseline in Cognitive Function Composite Score - Power of Attention — 1413.67; 1423.38; 1401.21; -5.86 msec — p=0.3771
Infections, Papillomavirus
Primary: Number of Subjects Reporting Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Cases Associated With HPV16 and/or HPV18 Detected Within the…
Anesthesia
Primary: Pa t/Pa0 Sevo (Arterial Partial Pressure of Sevoflurane), t=Time(Minutes) — 0.32; 0.44; 0.23; 0.32 ratio
Healthy
Primary: Endothelial Progenitor Cells — 0.101; 0.081 percentage of all lymphocytes — p=0.28
Urological
Primary: Mean and Standard Deviation of the Participant American Urological Association (AUA)Symptom Score Between Baseline and Week 72 for CAMUS Participants. — -2.20; -2.99…
Adhesive Tape Trauma
Primary: Skin Trauma — 0.93; 1.35 Units on a scale
Factor XIII Deficiency
Primary: Adverse Events — 42; 2; 2 participants
Obesity · Critical Illness
Primary: Plasma Concentration of Levofloxacin — 76 mg/L*hr
Contact Lens Wear
Primary: Change From Baseline in Ocular Comfort Rating at 2 Weeks — -8.20; -7.14 Units on a scale
Lung Neoplasms · Ovarian Neoplasms · Cervix Neoplasms
Primary: Geometric Mean of Maximum Concentration of the Drug (Cmax) — 1315; 1093; 1060; 1026 Cmax (ng/mL)